What was the primary driver of the significant increase in net income for the third quarter of 2002?

The primary driver of the significant increase in net income for the third quarter of 2002 was a $62 million after-tax credit resulting from litigation settlements related to rapid exchange catheter technology. This settlement significantly boosted the reported net income.

How is Boston Scientific addressing the competitive landscape in the coronary stent market, particularly with the upcoming launch of drug-eluting stents?

Boston Scientific launched its Express2™ coronary stent system in the U.S. in September 2002, which has positively impacted market share. The company is heavily investing in its TAXUS™ drug-eluting stent program, with ongoing clinical trials and plans for U.S. regulatory submission in Q2 2003, aiming for a Q4 2003 U.S. launch. They acknowledge the competitive pressure from other companies' drug-eluting stent launches in early 2003 and expect continued share and price pressure on their current stent business until their own drug-eluting stent is commercialized.

What is the status of the company's global operations strategy and its financial impact?

The company has substantially completed its plant optimization initiative, which is part of its global operations plan aimed at increasing productivity and improving resource allocation. While significant charges were incurred in prior periods and in early 2002 for restructuring costs, the company expects to achieve substantial pre-tax operating savings of approximately $220 million in 2002 and $250 million annually thereafter. These savings are primarily realized as reduced cost of sales and are partially reinvested in R&D.

What were the key recent acquisitions, and how are they expected to contribute?

In the second quarter of 2002, Boston Scientific acquired Enteric Medical Technologies, Inc. (EMT) for its Enteryx™ GERD treatment technology and BEI Medical Systems Company, Inc. (BEI) for its gynecological technology for treating uterine bleeding. These acquisitions are intended to expand the company's Endosurgery product offerings. The company anticipates revenues of approximately $200 million for 2002 associated with its 2001 and 2002 acquisitions.

BSX 10-Q Quarterly Report Q3 FY2002 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported solid financial results for the third quarter and first nine months of 2002, demonstrating a significant turnaround from the prior year. Net sales increased by 8% in Q3 2002 and 5% year-to-date, driven by growth across its product lines, particularly in Endosurgery and contributions from recent acquisitions. The company achieved a substantial increase in net income, reporting $161 million ($0.39/share diluted) for the third quarter, a significant jump from $58 million ($0.14/share diluted) in the prior year. This improvement was bolstered by a $62 million after-tax credit from litigation settlements. Excluding these one-time items, adjusted net income still showed a healthy increase, reflecting operational improvements and strategic execution. The company also highlighted progress in its global operations strategy, aiming for cost efficiencies and better resource allocation.

Key Highlights

1Net sales increased by 8% year-over-year to $722 million in Q3 2002 and by 5% year-to-date to $2,105 million.
2Net income saw a significant rise, with reported Q3 2002 net income at $161 million ($0.39/share diluted) compared to $58 million ($0.14/share diluted) in Q3 2001.
3The company benefited from a $62 million after-tax credit from litigation settlements in Q3 2002.
4Gross profit margin improved to 70.8% in Q3 2002 from 68.1% in Q3 2001, attributed to operational efficiencies and favorable product mix.
5Research and development expenses increased by 21% in Q3 2002, primarily driven by investments in the TAXUS drug-eluting stent program.
6The company completed two strategic acquisitions in the second quarter of 2002: Enteric Medical Technologies, Inc. (EMT) and BEI Medical Systems Company, Inc. (BEI).
7Boston Scientific entered into a revolving credit and security facility in August 2002, providing up to $200 million in additional borrowing capacity.

BOSTON SCIENTIFIC CORP Quarterly Report for Q3 Ended Sep 30, 2002

Summary

Key Highlights

Frequently Asked Questions